We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam & Medison Partner to Market RNAi Products in Israel
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) entered into an exclusive agreement with Israel’s leading pharmaceuticals partner, Medison Pharma to commercialize its newly approved RNAi therapeutic Onpattro in Israel.
Alnylam makes use of a potentially radical RNAi technology. This technology is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to make the genes silent selectively through RNAi holds the potential to change the way diseases are treated.
Share price of Alnylam has declined 36.6% in the past year compared with the industry’s decline of 20.2%.
We remind investors that Onpattro was approved in the United States and Europe in August 2018 for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved RNAi therapeutic for this indication and not approved for use in Israel. The agreement also includes Alnylam’s investigational late-stage RNAi therapeutics — givosiran, being developed for the treatment of acute hepatic porphyria (AHP), and lumasiran, which is being developed for the treatment of Primary Hyperoxaluria Type 1 (PH1). Both givosiran and lumasiran have not been approved by any regulatory authority yet.
The agreement with Medison is in sync with the company’s strategy to globally expand so that it can make treatments of rare diseases accessible to patients across the globe. Medison has been successful at commercializing orphan products. The company has an infrastructure that is uniquely suited to support patients suffering from rare diseases in Israel. Per the agreement, Medison will have access to Alnylam’s Onpattro and other candidates that it can make available to physicians and patients in Israel.
Alnylam’s expertise in RNAi therapeutics and broad intellectual property estate has allowed the company to enter into collaborations with leading pharmaceutical and life sciences companies like Ionis Pharmaceuticals, Novartis (NVS - Free Report) , Roche, Takeda, Merck (MRK - Free Report) The Medicines Company and Sanofi’s (SNY - Free Report) specialty care global business unit, Genzyme, among others.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Alnylam & Medison Partner to Market RNAi Products in Israel
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) entered into an exclusive agreement with Israel’s leading pharmaceuticals partner, Medison Pharma to commercialize its newly approved RNAi therapeutic Onpattro in Israel.
Alnylam makes use of a potentially radical RNAi technology. This technology is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to make the genes silent selectively through RNAi holds the potential to change the way diseases are treated.
Share price of Alnylam has declined 36.6% in the past year compared with the industry’s decline of 20.2%.
We remind investors that Onpattro was approved in the United States and Europe in August 2018 for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved RNAi therapeutic for this indication and not approved for use in Israel. The agreement also includes Alnylam’s investigational late-stage RNAi therapeutics — givosiran, being developed for the treatment of acute hepatic porphyria (AHP), and lumasiran, which is being developed for the treatment of Primary Hyperoxaluria Type 1 (PH1). Both givosiran and lumasiran have not been approved by any regulatory authority yet.
The agreement with Medison is in sync with the company’s strategy to globally expand so that it can make treatments of rare diseases accessible to patients across the globe. Medison has been successful at commercializing orphan products. The company has an infrastructure that is uniquely suited to support patients suffering from rare diseases in Israel. Per the agreement, Medison will have access to Alnylam’s Onpattro and other candidates that it can make available to physicians and patients in Israel.
Alnylam’s expertise in RNAi therapeutics and broad intellectual property estate has allowed the company to enter into collaborations with leading pharmaceutical and life sciences companies like Ionis Pharmaceuticals, Novartis (NVS - Free Report) , Roche, Takeda, Merck (MRK - Free Report) The Medicines Company and Sanofi’s (SNY - Free Report) specialty care global business unit, Genzyme, among others.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank
Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>